Glutamate Inhibitors in Glioblastoma

The goal of this 1:1 randomized, multi-center, open-label phase Ib/II clinical trial is to explore the efficacy of the add-on of the anti-glutamatergic drugs gabapentin, sulfasalazine and memantine to standard chemoradiotherapy with temozolomide compared to chemoradiotherapy alone in patients with newly diagnosed glioblastoma.

Trial Details

NCT ID

NCT05664464

Phase

PHASE1 / PHASE2

Sponsor

University of Zurich

Status

RECRUITING

Cancer Type

Glioblastoma (GBM) Brain Cancer

Interventions

Gabapentin
Sulfasalazine
Memantine
Temozolomide
Radiotherapy

Locations (sample)

Zurich, Canton of Zurich, Switzerland|47.36667,8.55

Key Eligibility Criteria

Diagnosis: Newly diagnosed supratentorial glioblastoma according to the 2021 World Health Organization (WHO) Classification of Central Nervous Syst…
Signed informed consent
Age \>18 years
Eligible for standard chemoradiotherapy with temozolomide (TMZ/RT-\>TMZ, hypofractionated RT regimen not allowed)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →